ALK and non-small cell lung carcinoma: In the phase II KEYNOTE-021 Cohort G (KN021G) trial of patients with advanced non squamous NSCLC without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) aberrations, the hazard ratio (HR) for overall survival (OS) with pembrolizumab + carboplatin + pemetrexed vs with pemetrexed + carboplatin alone was 0.56 (95% confidence interval [CI] 0.32‒0.95; p value = 0.015) after 24 months of follow-up [5].